Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-25
DOI
10.3389/fphar.2021.649143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
- (2020) Hong Deng et al. BMC Neurology
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
- (2020) Inge A. Mulder et al. ANNALS OF NEUROLOGY
- Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis
- (2020) Yousef Waleed Alasad et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis
- (2019) Lin Han et al. Brain and Behavior
- Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials
- (2019) Da Xu et al. CEPHALALGIA
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Monoclonal antibodies for the prevention of migraine
- (2019) Bianca Raffaelli et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
- (2019) Fumihiko Sakai et al. HEADACHE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Calcitonin-gene-related peptide pathway mAbs and migraine prevention
- (2018) Koen Paemeleire et al. CURRENT OPINION IN NEUROLOGY
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
- (2018) Yuhan Zhu et al. NEUROLOGICAL SCIENCES
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Side effects associated with current and prospective antimigraine pharmacotherapies
- (2017) Abimael González-Hernández et al. Expert Opinion on Drug Metabolism & Toxicology
- A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns
- (2017) Janet H. Ford et al. HEADACHE
- The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine
- (2017) Lars Edvinsson HEADACHE
- Prevalence and burden of headache disorders in Lithuania and their public-health and policy implications: a population-based study within the Eurolight Project
- (2017) Daiva Rastenytė et al. JOURNAL OF HEADACHE AND PAIN
- The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
- (2017) Min Hou et al. JOURNAL OF HEADACHE AND PAIN
- Blocking CGRP in migraine patients – a review of pros and cons
- (2017) Marie Deen et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey
- (2016) Andrew Messali et al. HEADACHE
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
- (2012) Georgia Salanti Research Synthesis Methods
- Treatment costs and indirect costs of cluster headache: A health economics analysis
- (2011) Charly Gaul et al. CEPHALALGIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now